Cogent Biosciences price to book ratio COGT

Market value divided by the book value of the company's net assets, since 2018.

Today, Oct 23, 2026: 10.2×
8-year median: 2.7×
Against its 8-year history: 90th; percentile: 0 is its lowest day, 100 its highest
8-year range: 0.3× to 19.8×
Peer median: 10.6×

Cogent Biosciences' price to book ratio is 10.2× as of Oct 23, 2026.

That is above its 8-year median of 2.7×, higher than on 90% of days in the last 8 years.

Over that time it ranged from 0.3× in Apr 2020 to 19.8× in Dec 2025.

The median for 10 large drugmakers of a similar size is 10.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	10.2×	8.5×	18.3×
2025	18.3×	1.9×	19.8×
2024	2.7×	1.2×	3.5×
2023	1.7×	1.4×	4.1×
2022	2.8×	1.0×	3.4×
2021	1.7×	1.0×	2.1×
2020	4.9×	0.3×	6.1×
2019	0.8×	0.6×	2.2×
2018	2.0×	2.0×	6.4×

Against its peers

Companies in Drug Manufacturers - General nearest Cogent Biosciences' size, closest first, today.

Company	Price to book ratio
COGTCogent Biosciences	10.2×
KNSAKiniksa Pharmaceuticals International	9.2×
LGNDLigand Pharmaceuticals	6.3×
AMRXAmneal Pharmaceuticals	197×
INDVIndivior Pharmaceuticals	n/m
ALKSAlkermes plc.	4.0×
ARQTArcutis Biotherapeutics	17.8×
LQDALiquidia	19.6×
OGNOrganon	3.6×
TGTXTG Therapeutics	13.7×
PTGXProtagonist Therapeutics	10.6×
Peer median	10.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Cogent Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.